Abstract
Immune responses are highly variable from one individual to another, with this variability determined by factors such as age, sex, genetics and environment, which also affect physical and mental well-being. Systems immunology studies have been applied to human cohort studies to better understand these effects, but most are performed in Western populations of mostly European ancestry, neglecting the vast majority of human global diversity. To overcome this limitation, we established the Healthy Human Global Project – Hong Kong (HHGP-HK) cohort to allow the study of immune variability in a healthy Asian population. Taking inspiration from the established French Milieu Interieur study we adapted inclusion and exclusion criteria to identify healthy donors, and to facilitate cross comparison between the two cohorts we collected similar demographic, medical and lifestyle information. To study the effects of age and sex, donors were stratified for both ranging from 20-79 years. We report here significant age and sex effects on multiple clinical laboratory measures, many of which were consistently observed in the Milieu Interieur cohort. C-reactive protein and liver enzymes were two exceptions perhaps reflecting different environmental effects between the two cohorts. We applied biological aging, physiological, and mental health scores to our cohort which highlights the need to develop and adapt such scores for application to populations of non-European descent. We also included wearable fitness trackers from which we observed significant age and sex differences for sleep, physical activity, and heart rate variability. This unique cohort will enable the better understanding of factors that determine immune variability within Asian populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by a grant from InnoHK, an initiative of the Innovation and Technology Commission, the Government of the Hong Kong Special Administrative Region
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The HHGP-HK clinical study protocol was first approved by the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB) on 16 August 2021 with reference number UW21-549. HHGP-HK is registered with the HKU Clinical Trial Registry (HKUCTR) and is available for public access on www.HKUCTR.com with study identifier HKUCTR-2959. The study is sponsored by the Centre for Immunology & Infection (C2i) and was conducted as a single center study at the University of Hong Kong without any investigational product. The protocol is registered under ClinicalTrials.gov (study number NCT05174624). Three subsequent HKU/HA HKW IRB clinical research ethics review approval amendments were obtained to adapt to recruitment challenges due to the COVID-19 pandemic.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos